Sector: Healthcare | Industry: Healthcare Facilities & Services |
Company Contact | |
Address: | Suite 2050 - 1055, West Georgia Street VANCOUVER BC V6E 3P3 |
Tel: | 1-514-5434200 |
Website: | https://www.cannara.ca/en |
IR: | See website |
Key People | ||
Zohar Krivorot Chairman of the Board, Chief Executive Officer | Nicholas Sosiak Chief Financial Officer | Avi Krivorot Chief Technology Officer |
Noemi Follain Vice President - Finance | Anthony Manouk Vice President - Compliance, General Manager |
Business Overview |
Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Company's brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis. |
Financial Overview |
For the three months ended 30 November 2023, Cannara Biotech Inc revenues increased 89% to C$19.5M. Net income increased from C$3K to C$2.1M. Revenues reflect Cannabis operations segment increase of 97% to C$18.6M, Real estate operations segment increase of 5% to C$909K. Net income benefited from Cannabis operations segment income increase from C$1.2M to C$3.3M, Real estate operations segment income increase of 7% to C$837K. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $123.43M as of Nov 30, 2023 |
Annual revenue (TTM): | $66.73M as of Nov 30, 2023 |
EBITDA (TTM): | -$5.13M as of Nov 30, 2023 |
Net annual income (TTM): | $9.05M as of Nov 30, 2023 |
Free cash flow (TTM): | -$2.28M as of Nov 30, 2023 |
Net Debt Last Fiscal Year: | $46.02M as of Nov 30, 2023 |
Shares outstanding: | 90,018,952 as of Dec 12, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |